FINWIRES · TerminalLIVE
FINWIRES

$NTRA

9 stories mentioning NTRA

Every FINWIRES story that references NTRA, newest first.

Sectors

Sector Update: Healthcare Stocks Mixed Pre-Bell Friday

Healthcare stocks were mixed pre-bell Friday, with the State Street Health Care Select Sector SPDR ETF (XLV) down 0.1% and the iShares Biotechnology ETF (IBB) 0.3% higher.Tempus AI (TEM) shares were up more than 6% after the company said it has received approval from the US Food and Drug Administration for a tumor-only indication for its xT CDx next-generation sequencing platform used for comprehensive genomic profiling of solid tumors.Agios Pharmaceuticals (AGIO) stock was down more than 3% after the company said it will discontinue development of tebapivat for lower-risk myelodysplastic syndromes after a phase 2b study failed to meet the company's threshold for further advancement.Natera (NTRA) shares were up more than 1% after the company said Diakonos Oncology will use its Signatera test to assess molecular response in patients with refractory melanoma enrolled in its DOC-RM phase I/II investigational immunotherapy trial.

$AGIO$IBB$NTRA$TEM$XLV
Sectors

Sector Update: Healthcare Stocks Advance Premarket Tuesday

Healthcare stocks were advancing premarket Tuesday, with the iShares Biotechnology ETF (IBB) 0.4% higher and the State Street Health Care Select Sector SPDR ETF (XLV) up 0.2%.Eli Lilly (LLY) has agreed to acquire Curevo, LimmaTech Biologics, and Vaccine Company in deals worth up to nearly $3.83 billion in total, expanding its presence in infectious disease prevention, the company said. Shares of Eli Lilly were up more than 1% pre-bell.Natera (NTRA) stock was up more than 2% after the company said it has upgraded its Panorama non-invasive prenatal test using SNP-informed deep sequencing to improve accuracy in samples with low fetal fraction.Jade Biosciences (JBIO) has dosed the first participant in its phase 2 trial of experimental therapy, JADE101, for immunoglobulin A nephropathy, or IgAN, the drugmaker said. Shares of Jade Biosciences were up more than 5% premarket.

$IBB$JBIO$LLY$NTRA$XLV
Sectors

Sector Update: Healthcare Stocks Edge Higher Premarket Wednesday

Healthcare stocks were edging higher premarket Wednesday, with the State Street Health Care Select Sector SPDR ETF (XLV) up 0.3% and the iShares Biotechnology ETF (IBB) advancing by 0.8%.Roivant Sciences (ROIV) stock was up nearly 6% after the company reported that it swung to a fiscal Q4 net income.ImmunityBio's (IBRX) supplemental biologics license application for Anktiva in combination with Bacillus Calmette-Guerin in patients with bladder cancer with papillary disease has been accepted for review by the US Food and Drug Administration, the company said. ImmunityBio shares were 8% higher pre-bell.Natera (NTRA) stock was up more than 2% after the company said the trial evaluating its Fetal Focus single-gene noninvasive prenatal test has enrolled more than 2,000 patients, more than doubling enrollment over the past year.

$IBB$IBRX$NTRA$ROIV$XLV
Wire

Natera's Signatera CDx Approved by FDA as Companion Diagnostic in Muscle-Invasive Bladder Cancer

Natera (NTRA) said Friday the US Food and Drug Administration approved Signatera CDx as a companion diagnostic for use with adjuvant atezolizumab to treat muscle-invasive bladder cancer.The approval follows phase 3 trial results that showed Signatera molecular residual disease-positive patients treated with immunotherapy achieved improvements in disease-free survival and overall survival, while MRD-negative patients achieved 97% two-year OS with no adjuvant therapy, the company said.Price: $189.00, Change: $-7.91, Percent Change: -4.02%

$NTRA
Wire

Natera Q1 Net Loss Widens, Revenue Rises; Shares Drop After Hours

Natera (NTRA) reported a Q1 net loss late Thursday of $0.60 per diluted share, widening from the loss of $0.50 a year earlier.Analysts polled by FactSet expected a loss of $0.54.Revenue in the three months ended March 31 rose to $696.6 million from $501.8 million a year earlier.Analysts surveyed by FactSet expected $617.1 million.The company boosted full-year revenue guidance to $2.74 billion to $2.82 billion from the previous forecast of $2.62 billion to $2.70 billion.Analysts expect $2.67 billion.Natera shares fell 4.5% in after-hours trading.

$NTRA
Insider Trading

Natera Insider Sold Shares Worth $693,560, According to a Recent SEC Filing

Solomon Moshkevich, President of Clinical Diagnostics, on May 01, 2026, sold 3,405 shares in Natera (NTRA) for $693,560. Following the Form 4 filing with the SEC, Moshkevich has control over a total of 142,295 common shares of the company, with 142,295 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1604821/000201001926000013/xslF345X05/form4-05052026_090506.xml

$NTRA
Insider Trading

Natera Insider Sold Shares Worth $1,191,775, According to a Recent SEC Filing

Steven Leonard Chapman, Director, Chief Executive Officer and President, on April 27, 2026, sold 5,838 shares in Natera (NTRA) for $1,191,775. Following the Form 4 filing with the SEC, Chapman has control over a total of 150,769 common shares of the company, with 150,769 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1604821/000171196826000010/xslF345X05/form4-04292026_090410.xml

$NTRA
Insider Trading

Natera Insider Sold Shares Worth $1,001,645, According to a Recent SEC Filing

Michael Burkes Brophy, Chief Financial Officer, on April 27, 2026, sold 5,063 shares in Natera (NTRA) for $1,001,645. Following the Form 4 filing with the SEC, Brophy has control over a total of 58,291 common shares of the company, with 58,291 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1604821/000169736226000008/xslF345X05/form4-04292026_090402.xml

$NTRA
Research

William Blair Initiates Natera at Outperform

Natera (NTRA) has an average rating of buy and mean price target of $258.20, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$NTRA